Literature DB >> 16967754

Methamphetamine use among marginalized youth in British Columbia.

Ian Martin1, Thomas M Lampinen, Doug McGhee.   

Abstract

BACKGROUND: Crystal methamphetamine (MA) is a powerful, highly addictive central nervous stimulant that can cause serious health consequences including neurotoxicity, paranoia, psychosis, depression, violence, and death. The objective of this study is to assess the prevalence and characteristics of MA use among two marginalized populations of youth (less than 30 years of age) in British Columbia.
METHODS: A self-administered questionnaire was administered to a convenience sample of Vancouver street-involved youth (SY) and Lesbian/Gay/Bisexual/Transgender/Questioning (LGBTQ) centre youth in Vancouver and Victoria. Items measured include: participants' demographic characteristics; illicit substance use, including details of MA use; attempts at recovery and treatment; and potential consequences of MA use.
RESULTS: One hundred and eighty of the 200 questionnaires distributed were completed. Sixty-seven percent of the SY and 24% of the LGBTQ youth reported ever having used MA. Of these: 43% had used within the last week; 46-57% used multiple times per day in their lifetime; they spent a maximum of 7-9 consecutive days awake; they began use in their middle to late teens; and half had sought help for a substance use disorder. SY who used MA within the last week were more likely to also use marijuana, cigarettes, heroin, ecstasy, and ketamine. Previous use of MA was associated with reports of auditory hallucinations.
CONCLUSION: The current study demonstrates a high prevalence of MA use in two marginalized populations of youth. Use in sexual minorities, resulting psychopathology, and concurrent substance use all have important implications in delivery of service, prevention, and subsequent research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16967754      PMCID: PMC6976223     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  7 in total

1.  Research reawakens ecstasy neurotoxicity debate.

Authors:  Kelly Morris
Journal:  Lancet Neurol       Date:  2003-11       Impact factor: 44.182

Review 2.  Self-report among injecting drug users: a review.

Authors:  S Darke
Journal:  Drug Alcohol Depend       Date:  1998-08-01       Impact factor: 4.492

Review 3.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

4.  A risk profile of street youth in northern California: implications for gender-specific human immunodeficiency virus prevention.

Authors:  K Clements; A Gleghorn; D Garcia; M Katz; R Marx
Journal:  J Adolesc Health       Date:  1997-05       Impact factor: 5.012

5.  Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET.

Authors:  Y Sekine; M Iyo; Y Ouchi; T Matsunaga; H Tsukada; H Okada; E Yoshikawa; M Futatsubashi; N Takei; N Mori
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

Review 6.  A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men.

Authors:  P N Halkitis; J T Parsons; M J Stirratt
Journal:  J Homosex       Date:  2001

Review 7.  Will the methamphetamine problem go away?

Authors:  Richard A Rawson; M Douglas Anglin; Walter Ling
Journal:  J Addict Dis       Date:  2002
  7 in total
  18 in total

1.  Frequent methamphetamine injection predicts emergency department utilization among street-involved youth.

Authors:  B D L Marshall; E Grafstein; J A Buxton; J Qi; E Wood; J A Shoveller; T Kerr
Journal:  Public Health       Date:  2011-11-30       Impact factor: 2.427

2.  Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting.

Authors:  Nadia Fairbairn; Thomas Kerr; Jane A Buxton; Kathy Li; Julio S Montaner; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2006-12-01       Impact factor: 4.492

Review 3.  The burden and management of crystal meth use.

Authors:  Jane A Buxton; Naomi A Dove
Journal:  CMAJ       Date:  2008-06-03       Impact factor: 8.262

4.  Repeated co-administrations of alcohol- and methamphetamine-produced anxiogenic effect could be associated with the neurotoxicity in the dentate gyrus.

Authors:  Jia-Ying Chuang; Wan-Ting Chang; Chianfang G Cherng; Gour-Shenq Kao; Lung Yu
Journal:  J Neural Transm (Vienna)       Date:  2011-04-17       Impact factor: 3.575

5.  A Promising Route Towards Improvement of Homeless Young People's Access to Mental Health Services: The Creation and Evolution of an Outreach Service Network in Montréal.

Authors:  Raphaël Morisseau-Guillot; Diane Aubin; Julie-Marguerite Deschênes; Milena Gioia; Ashok Malla; Pasquale Bauco; Marie-Ève Dupont; Amal Abdel-Baki
Journal:  Community Ment Health J       Date:  2019-10-12

6.  Correlates of risky alcohol and methamphetamine use among currently homeless male parolees.

Authors:  Benissa E Salem; Adeline Nyamathi; Colleen Keenan; Sheldon Zhang; Elizabeth Marlow; Farinaz Khalilifard; Kartik Yadav; Mark Faucette; Barbara Leake; Mary Marfisee
Journal:  J Addict Dis       Date:  2013

7.  Bottoms up: methamphetamine toxicity from an unusual route.

Authors:  Malkeet Gupta; Scott Bailey; Luis M Lovato
Journal:  West J Emerg Med       Date:  2009-02

8.  Initiation into methamphetamine use for young gay and bisexual men.

Authors:  Jeffrey T Parsons; Brian C Kelly; Jonathan D Weiser
Journal:  Drug Alcohol Depend       Date:  2007-03-29       Impact factor: 4.492

9.  Methamphetamine use and rates of incarceration among street-involved youth in a Canadian setting: a cross-sectional analysis.

Authors:  M-J Milloy; Thomas Kerr; Jane Buxton; Julio Montaner; Evan Wood
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-08-12

10.  Drug use and barriers to and facilitators of drug treatment for homeless youth.

Authors:  Adeline Nyamathi; Angela Hudson; Malaika Mutere; Ashley Christiani; Jeff Sweat; Kamala Nyamathi; Theresa Broms
Journal:  Patient Prefer Adherence       Date:  2007-10-24       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.